Literature DB >> 10439929

Current guidelines for the treatment and prevention of nosocomial infections.

E Bergogne-Bérézin1.   

Abstract

Nosocomial infections (NIs) are among the most difficult problems confronting clinicians who deal with severely ill patients. The incidence of these hospital-acquired infections varies with the size of hospitals, with specialities of wards, and with many other factors such as length of hospital stay, local trends in antibiotic usage, nursing and hygiene conditions, hospital design and geographical distribution of patients at risk. An average incidence of NI can be estimated at 5 to 10%, with higher rates in large university hospitals, reaching up to 28% in the intensive care unit (ICU). Changing epidemiology of NI and emerging resistance problems have resulted in evolving strategies of antibiotic usage in patients at risk. Several recent antibiotic resistance problems have been identified, for instance in Gram-positive organisms, and have been surveyed, in addition to those previously well known in Gram-negative bacilli. The choice of empiric antibiotic therapy for the treatment of any NI before microbiology is available has become a difficult challenge, requiring: (i) surveillance data on a regular basis of predominant organisms in units at risk; (ii) surveillance of the current resistance patterns of these organisms; (iii) identification of outbreaks involving the prevalent organisms, using modern molecular techniques for typing the strain and assess cross-contamination. In documented infection, monotherapy vs combination therapy has been often discussed in the treatment of serious Gram-negative hospital infections, but these concepts vary with the site of infection, the nature of organism involved and its pattern of resistance, the kind of antibiotic which may more or less quickly select resistant mutants. Antibiotic therapy concepts vary significantly between countries, and combinations either empirical or based on laboratory data are often preferred in European countries than in the US. Frequent collaborative studies and an increasing communication between experts of different countries, make guidelines and consensus conferences, established in a particular country, useful elsewhere and may contribute to improvement in the management of NI. Guidelines for the prevention and the control of NI are well established in many developed countries and they may have resulted in the improvement of the prevention and the treatment of NI. However, there is still potential progress that should be made, including individual preventive practices, improvement in nursing practices, control of antibiotic use, trend to shorten the hospital stay and early discharge from hospital, which results in significant cost savings.

Entities:  

Mesh:

Year:  1999        PMID: 10439929     DOI: 10.2165/00003495-199958010-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  63 in total

1.  Emergence of resistance during selective decontamination of the digestive tract.

Authors:  F Daschner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

Review 2.  Current guidelines for antibiotic prophylaxis of surgical wounds.

Authors:  R K Woods; E P Dellinger
Journal:  Am Fam Physician       Date:  1998-06       Impact factor: 3.292

3.  Guidelines for prevention of nosocomial pneumonia. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1997-01-03

4.  Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program.

Authors:  G S Itokazu; J P Quinn; C Bell-Dixon; F M Kahan; R A Weinstein
Journal:  Clin Infect Dis       Date:  1996-10       Impact factor: 9.079

5.  Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study.

Authors:  A J Clavo-Sánchez; J A Girón-González; D López-Prieto; J Canueto-Quintero; A Sánchez-Porto; A Vergara-Campos; P Marín-Casanova; J A Córdoba-Doña
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

6.  Susceptibility of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over a 5-year period.

Authors:  R E Kessler; J Fung-Tomc
Journal:  Am J Med       Date:  1996-06-24       Impact factor: 4.965

Review 7.  Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary.

Authors:  J W Chow; V L Yu
Journal:  Int J Antimicrob Agents       Date:  1999-01       Impact factor: 5.283

Review 8.  Stenotrophomonas (Xanthomonas) maltophilia: a multidrug-resistant nosocomial pathogen.

Authors:  S R Penzak; B J Abate
Journal:  Pharmacotherapy       Date:  1997 Mar-Apr       Impact factor: 4.705

Review 9.  Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance.

Authors:  P K Linden
Journal:  Am J Med       Date:  1998-05-29       Impact factor: 4.965

10.  Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection.

Authors:  M B Edmond; J F Ober; D L Weinbaum; M A Pfaller; T Hwang; M D Sanford; R P Wenzel
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

View more
  3 in total

Review 1.  Linezolid: a review of its use in the management of serious gram-positive infections.

Authors:  C M Perry; B Jarvis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Challenges in using the Arden Syntax for computer-based nosocomial infection surveillance.

Authors:  R A Jenders; A Shah
Journal:  Proc AMIA Symp       Date:  2001

Review 3.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.